8-K: N2OFF Extends MitoCareX Acquisition Timeline and Provides Additional $250,000 Loan

N2OFF, Inc. extends the exclusivity period for its acquisition of MitoCareX Bio Ltd. and provides an additional $250,000 loan to support MitoCareX's ongoing operations.

Summary

• N2OFF, Inc. has amended its Securities Purchase and Exchange Agreement with MitoCareX Bio Ltd., SciSparc Ltd., Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri to extend the exclusivity period for the acquisition of MitoCareX by 90 days.
• The new deadline for the closing date is 180 days from the original agreement date.
• N2OFF has also entered into a third loan agreement with MitoCareX, providing a $250,000 loan with interest accruing at an annual rate of the USD exchange rate fluctuation until maturity plus 3%.
• The loan term is six months, with principal and accrued interest due at maturity.
• L.I.A. Pure Capital Ltd. is guaranteeing the repayment of the loan.
• The purpose of the loan is to assist MitoCareX with financing its ongoing costs and obligations until the acquisition closes.
• N2OFF also amended two prior loan agreements with MitoCareX from December 22, 2024, and March 12, 2025, extending the term of each loan by 180 days.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the extension of the exclusivity period and the additional loan suggest continued commitment to the acquisition, they also indicate potential challenges in finalizing the deal and MitoCareX's need for additional funding.

Positives

• The extension of the exclusivity period suggests continued interest in completing the acquisition of MitoCareX.
• The additional loan provides MitoCareX with necessary funding to continue operations.
• The loan agreements include guarantees from L.I.A. Pure Capital Ltd., reducing N2OFF's risk.

Negatives

• The extension of the exclusivity period could indicate challenges in finalizing the acquisition agreement.
• The need for additional loans may suggest that MitoCareX is facing financial difficulties.
• The loan terms include interest based on the USD exchange rate fluctuation plus 3%, which could be costly if the exchange rate increases.

Risks

• The acquisition of MitoCareX may not be completed if the closing date is not met within the extended timeframe.
• MitoCareX may be unable to repay the loans if the acquisition does not occur.
• Fluctuations in the USD exchange rate could increase the cost of the loans for MitoCareX.

Future Outlook

The document indicates N2OFF's continued intention to acquire MitoCareX, with the extended exclusivity period allowing more time to finalize the transaction. The additional loan provides MitoCareX with short-term financial support.

Industry Context

This announcement reflects a trend of companies using loans and acquisitions to expand their operations and market presence. The extension of the exclusivity period suggests that the acquisition process is complex and may require additional time to complete due diligence and negotiate final terms.

Comparison to Industry Standards

• It is common for companies in the biotech and pharmaceutical industries to use loans to finance ongoing operations, especially during acquisition processes.
• The interest rate on the loan, based on the USD exchange rate fluctuation plus 3%, is within the typical range for short-term loans in Israel.
• Extending exclusivity periods in acquisition agreements is also a common practice when additional time is needed to finalize the deal.

Stakeholder Impact

• Shareholders of N2OFF may be impacted by the potential acquisition of MitoCareX and the associated financial commitments.
• Employees of MitoCareX may be affected by the acquisition, depending on the integration plans.
• The loan provides MitoCareX with the financial resources to meet its obligations to suppliers and creditors.

Next Steps

• N2OFF and MitoCareX will continue to work towards finalizing the acquisition agreement within the extended exclusivity period.
• MitoCareX will use the loan proceeds to finance its ongoing costs and obligations.
• The parties will monitor the USD exchange rate to manage the interest expense on the loan.

Key Dates

Keywords

acquisition, loan agreement, MitoCareX, N2OFF, exclusivity period, financing